Literature DB >> 19713999

Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development.

D D Rao1, N Senzer, M A Cleary, J Nemunaitis.   

Abstract

This review considers comparisons of the off-target effects of siRNA to shRNA and their potential impact on the efficacy and toxicity of RNAi based therapeutics.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19713999     DOI： 10.1038/cgt.2009.53

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


  43 in total

1.  miR-31 functions as a negative regulator of lymphatic vascular lineage-specific differentiation in vitro and vascular development in vivo.

Authors:  Deena M Leslie Pedrioli; Terhi Karpanen; Vasilios Dabouras; Giorgia Jurisic; Glenn van de Hoek; Jay W Shin; Daniela Marino; Roland E Kälin; Sebastian Leidel; Paolo Cinelli; Stefan Schulte-Merker; André W Brändli; Michael Detmar
Journal:  Mol Cell Biol       Date:  2010-05-17       Impact factor: 4.272

2.  Reduced seed region-based off-target activity with lentivirus-mediated RNAi.

Authors:  Richard A Klinghoffer; Jill Magnus; Janell Schelter; Michele Mehaffey; Casey Coleman; Michele A Cleary
Journal:  RNA       Date:  2010-03-26       Impact factor: 4.942

3.  Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.

Authors:  Jorge F Coelho; Paula C Ferreira; Patricia Alves; Rosemeyre Cordeiro; Ana C Fonseca; Joana R Góis; Maria H Gil
Journal:  EPMA J       Date:  2010-04-10       Impact factor: 6.543

Review 4.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

5.  Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.

Authors:  Michael D Blough; Desiree C Beauchamp; Morgan R Westgate; John J Kelly; J Gregory Cairncross
Journal:  J Neurooncol       Date:  2010-07-01       Impact factor: 4.130

Review 6.  Personalized cancer approach: using RNA interference technology.

Authors:  John Nemunaitis; Donald D Rao; Shi-He Liu; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

Review 7.  MicroRNAs, cancer and cancer stem cells.

Authors:  Amy L Zimmerman; Shiyong Wu
Journal:  Cancer Lett       Date:  2010-10-20       Impact factor: 8.679

8.  The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.

Authors:  Biji Mathew; Frances E Lennon; Jessica Siegler; Tamara Mirzapoiazova; Nurbek Mambetsariev; Saad Sammani; Lynnette M Gerhold; Patrick J LaRiviere; Chin-Tu Chen; Joe G N Garcia; Ravi Salgia; Jonathan Moss; Patrick A Singleton
Journal:  Anesth Analg       Date:  2010-12-14       Impact factor: 5.108

9.  RNAi-induced synthetic lethality in cancer therapy.

Authors:  Bingbing Dai; Bingliang Fang; Jack A Roth
Journal:  Cancer Biol Ther       Date:  2009-12-06       Impact factor: 4.742

10.  Experimental and Computational Considerations in the Study of RNA-Binding Protein-RNA Interactions.

Authors:  Eric L Van Nostrand; Stephanie C Huelga; Gene W Yeo
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.